• Natural Reconstruction


    Improving the quality of life of breast cancer survivors.


    Every year, more than 2.8 million women undergo breast surgery. Based on the number of breast cancer diagnosis and statistics of tumor resections, we estimated that in 2017 approx. 956,000 women worldwide underwent reconstructive surgery after a mastectomy or a lumpectomy (i.e. total or partial breast removal, respectively) and ~226,000 breast surgery revisions have been performed. According to the International Society of Plastic Surgery (ISAPS), breast augmentation represents the world’s leading aesthetic surgical procedure, with ~1.65 million operations performed in 2016. The most commonly used technologies for breast tissue defects are silicone or saline implants. These prostheses are not lifetime devices and need to be substituted over time, leading to high costs for the healthcare stakeholders and significant pain for the patients. Moreover, silicone implants do not represent a solution for patients who are eligible for a breast-conserving surgery (lumpectomy) since they are not customizable based on the defect size.

  • EU H2020 project "REGENERA"

    With the goal of solving these problems, Tensive created the project REGENERA to develop a cell-free porous scaffold made of resorbable biomaterials with a biomimetic architecture which aims to promote blood vessels and soft tissue recruitment. It is designed to be gradually replaced by the patients’ soft tissue, allowing to restore a natural aspect and feeling of the reconstructed breast. The technology has not yet been tested in humans.


    REGENERA project has been funded by the European Union's Horizon 2020 research and innovation programme, under grant agreement No 812002, for a total budget of €2.69 million. The goal of the project is to complete the development of a breakthrough solution for breast reconstruction, in particular for post-lumpectomy patients, for whom there are no definitive, optimal reconstructive options available.

  • About

    Expected Advantages.


    Clinical validation required. The technology has not yet been tested in humans.


    Natural shape


    No reoperation required


    Single surgery


    No leakage & ruptures


    Restoration of a natural sensation


    Not masking recurrences


    Procedure for surgeons


    For breast cancer survivors

  • News

    October 26, 2021
    Tensive started the First in Human clinical trial of its reconstruction indication in localized non-malignant breast lesions in Italy.  
    More Posts
  • Our Blog

    REGENERA's updates and news

  • Contact Us

    Headquarters: Viale Ortles 22/4, 20139, Milano (Italy)
    Registered Office: Via Timavo, 34 20124 Milano (Italy)
    +39 (0) 2 5666 0153
    All Posts